Influence of Paternal Age on Assisted Reproduction Outcome (MALE AGING)
In the recent years, there is an increasing tendency to the parenthood delay in developed countries, and there is not enough information available regarding the influence of the male's age on fertility. If any, the negative impact should be acting at advanced ages.
Our aim with this work was to determine the role of paternal age on IUI results embryo quality and IVF outcome. Evenmore, in order to standardize the female factor, good quality oocytes (from fertile oocyte donors) and only first IVF cycles in young women were considered.
Study Overview
Status
Conditions
- We Will Retrospectively Assess Our Databases in Our Clinic
- Instituto Valenciano de Infertilidad in Valencia (Spain)
- Searching for Assisted Reproduction Procedures
- IUI Standard IVF/ICSI Cycles and Ovum Donation IVF/ICSI Cycles
- Who Were Referred to Our Unit to Cryopreserve Sperm During the Period
- From January 2000 to December 2006
Detailed Description
A retrospective study has been designed with a total number of 2204 IUI, 1286 IVF cycles and 1412 IVF cycles with donated oocytes from 2000 to 2006.
The inclusion criteria will be for IUI: women under 38 years old, tubal patency demonstrated by hysterosalpingography, normal uterine scan, normal basal hormonal levels, body mass index < 27 kg/m2, and absence of polycystic ovarian syndrome and endometriosis. For normal IVF cycles and oocyte donation cycles only first cycles will be analyzed. Cycles will be studied only in couples with absence of severe male factor.
Study Type
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46015
- IVI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women under 38 years old, tubal patency demonstrated by hysterosalpingography, normal uterine scan, normal basal hormonal levels, body mass index < 27 kg/m2.
Exclusion Criteria:
- absence of polycystic ovarian syndrome, hydrosalpinx or endometriosis.
- Cycles were studied only in couples with absence of severe male factor.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Investigators
- Principal Investigator: Marcos Meseguer, PhD, IVI Valencia
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- VLC-MM-0205-507-26
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on We Will Retrospectively Assess Our Databases in Our Clinic
-
Wuhan UniversityPeking University; PfizerUnknownThe Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores. | The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales. | Safety Evaluations Include: Laboratory Test Abnormalities; BARS... and other conditions